UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 OR15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of October 2019
Commission File Number:001-38746
Taiwan Liposome Company, Ltd.
(Translation of registrant’s name into English)
Taiwan Liposome Company, Ltd.
11F-1, No. 3 Yuanqu Street
Nangang District,
Taipei City, Taiwan 11503
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F:
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Completion of 2019 cash capital offering of common shares
In October 2019, Taiwan Liposome Company, Ltd. (the “Company”) issued a press release announcing the completion of 2019 cash capital offering of common shares in Taiwan.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Exhibits
Exhibit Number | Exhibit Description | |
99.1 | Press release, dated October 24, 2019, entitled “TLC Announces Completion of US$27 Million Financing.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
TAIWAN LIPOSOME COMPANY, LTD. | ||||||
Date: October 24, 2019 | By: | /s/ George Yeh | ||||
Name: | George Yeh | |||||
Title: | President |